All News

PS0103 #EULAR2021. Do you adjust complement levels by time of pregnancy? ⭐️Mean C3 ⬆️28% compared to 1st trimester ⭐️Mean C4 ⬆️ 11% compared to 1st trimester @RheumNow

Eric Dein ejdein1 ( View Tweet)

Jun 05, 2021

#EULAR LB0003 Pfizer #COVID vax immunogenicity and safety in 686 rheum pts in Israel ⭐️Sero+ for COVID Ab 86% in RMD vs 100% controls ⭐️RTX lowest seropos of 39%, related to time of infusion ⭐️⬇️ with GC, ABA, MMF ⭐️ MTX not seen to significantly ⬇️ @RheumNow @rheum_covid

Eric Dein ejdein1 ( View Tweet)

Jun 05, 2021

#POS0022 prosp study of CTZ pregnancies: 1392 preg w/1425 outcomes @UCBUSA database 88.4% live births, 10.5% preg loss, 0.8% still birth 2.4% congen malform (w/2.1% major) Preg loss⬅️Crohn's, NSAIDS, MTX Preterm labor⬅️GCs, maternal infx ⬇️birth wt⬅️RA & GCs @rheumnow #EULAR2021 https://t.co/qnNcDIz8Ge

k dao KDAO2011 ( View Tweet)

Jun 05, 2021

#EULAR2021 and EULAR IQ Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021. https://t.co/BkHjhOUqNU https://t.co/4JS1yGiJHg

Links:

https://bit.ly/3fS5SJX

Dr. John Cush RheumNow ( View Tweet)

Jun 05, 2021

EULAR 2021 - Day 2 Podcasts

Save

d Jack Cush, MD

Jun 04, 2021

Check out this compilation of our EULAR 2021 Day 2 broadcasts below.

You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com

Listen by Clicking below:

Read Article

RheumNow Podcast - EULAR 2021 & EULAR-IQ (6.4.21)

Save

d Jack Cush, MD

Jun 04, 2021

Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.

Read Article

EULAR Best Abstracts - Day 2

Save

d Jack Cush, MD

Jun 04, 2021

The second day of EULAR 2021 took a big leap in online content. #EULAR2021 generated 2500 tweets yesterday. Here is a compilation (with links) of presentations were the “Best” as seen by our RheumNow faculty.

Read Article

EULAR 2021 – Day 2 Report

Save

d Jack Cush, MD

Jun 04, 2021

During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more. Here are some of my highlights from Day 2.

Read Article

New insights in RA-ILD therapeutics

Save

d Aurelie Najm, MD, PhD

Jun 04, 2021

RA associated ILD (RA-ILD) is the most common extra-articular manifestation in RA. Its prevalence varies considerably, ranging from 5% to 30%, and is often underestimated since patients only become symptomatic or display abnormalities on chest X-Ray at a late stage of disease, leading to subsequent delay in diagnosis. In this context, several groups advocate for an earlier and more precise detection, using high resolution chest computed tomography (HRCT), which is the most sensitive for pre-clinical RA-ILD diagnosis.
But why would we want to diagnose early a manifestation that we cannot treat?

Read Article

Serious infections and BioDMARDs: what is the confounding factor? BSRBR-RA: 33,916 RA treated w/ BioDMARDs with 62,532 years of follow-up, 2036 SI. HR of SI no longer different among BioDMARDs when adjusted for the line of therapy! #OP0241@Rheumnow #EULAR2021 https://t.co/UG9WrXP7RD

Aurelie Najm AurelieRheumo ( View Tweet)

Jun 04, 2021

2021 GRAPPA STRONG recs (cont'd): *⃣Crohn's Dz & UC: TNFi (not ETN), IL12/23i 🚫strong rec against IL17i 2021 GRAPPA CONDITIONAL recs for: *⃣ Uveitis: TNFi (not ETN), CyA *⃣ Crohn's Dz & UC: IL23i, JAKi, MTX OP0229 #EULAR2021 @RheumNow https://t.co/AWyKqSapWG

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Jun 04, 2021

Lower ILD incidence in PsA than RA in a large Nordic registry ⭐️ No significant ⬆️ in ILD in those using MTX Abs#OP0222 #EULAR2021 @RheumNow https://t.co/lgGhu1Hmd6

Robert B Chao, MD doctorRBC ( View Tweet)

Jun 04, 2021

#OP0228 Phase 3 RCT on Risankizumab - KEEPsAKE 2 -PsA with 49% prior bDMARD 95% prior csDMARD: week 24 results PE: ACR20 51% active vs 26% on PLC PASI90: 55% active vs. 10% PLC #EULAR2021 @RheumNow https://t.co/UkZLcXTNnq

Paul Studenic Stiddyo ( View Tweet)

Jun 04, 2021

➡️COMPLETE-AS = obs study of bDMARD-naive Canadians w/ active AS tx w/ ADA or nbDMARDS/NSAID. ➡️> overall⬇️in dz burden & shorter time to achieve therapeutic response w/ ADA. But, ADA pts had higher b/l dz OP0143 #EULAR2021 @RheumNow https://t.co/FpJmugsdVw

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Jun 03, 2021

⭐️All cancer excluding NMSC - 0.9HR TNFi vs cDMARD ⭐️Squamous cell CA - 1.2HR of TNFi vs cDMARD ⭐️No overall increase in all CA: RTX, TOCI ⭐️Abatacept 1.21HR for all cancer, mainly NMSC ⭐️needs more data on JAKs, IL-17, IL-23 Abs#6916 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

Jun 03, 2021

Leave my MTX alone says pt & #rheumatologist if pt has chronic ILD. Acute pneumonia from MTX is NOT chronic ILD in RA @RheumNow @eular_org #EULAR2021 #BoehringerIngelheim RA ILD silent killer symposium https://t.co/IQTINuUpVq

Janet Pope Janetbirdope ( View Tweet)

Jun 03, 2021

#POS0196 1 year results of the SELECT-PsA 2 study: Inadequate responders to ≥1bDMARD subjected to #upadacitinib maintained efficacy throughout week 56 (74% of pts completed 1-year) #EULAR2021 @RheumNow https://t.co/xpqhzgeI6q

Paul Studenic Stiddyo ( View Tweet)

Jun 03, 2021

#EULAR2021 OP0133 retinal toxicity with HCQ use. ⬆️ risk: ⭐️Duration 10-14.9 yr (OR 5) ⭐️Duration >15 yr (OR 19) ⭐️Dose >7 mg/kg/d (OR 4.6) ⭐️Cum dose >2000 g Atherosclerosis, age >80 seen in multi-var analysis But didn't have HCQ levels to predict risk @MaxKonigMD @RheumNow https://t.co/DzWWm0U64L

Eric Dein ejdein1 ( View Tweet)

Jun 03, 2021

No requirement to stop cDMARDs before surgery. For biologics stop 1 dose before and restart 14 days post op, JAKi stop 7 days before, restart 14 days post op, glucocorticoids >10mg/day increases risk of infection in #rheumatoidarthritis Michael D George #EULAR2021

Dr. Antoni Chan synovialjoints ( View Tweet)

Jun 03, 2021

#EULAR Presentation 3478: Infection risk with surgeries: ⭐️Continue conventional DMARD ⭐️Some risk with biologics, may be confounder and no association with timing of infusions ⭐️Steroids are major risk factor! Esp >10 mg/d ⭐️Recommendations shown ⭐️Address other risks! @rheumnow https://t.co/Bi02d4p9Mw

Eric Dein ejdein1 ( View Tweet)

Jun 03, 2021

Topics